Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Ltd is primarily engaged in the manufacturing and trading of pharmaceutical products and APIs. It has operations in India and caters to both domestic and international markets.
What Jagsonpal files
- Others57
- Important36
- Investor Meet36
- Updates18
- Dividend/Bonus9
- Board Meeting7
Jagsonpal Pharmaceuticals reported stable financial results for the quarter and nine months ended December 31, 2025. 1. **Business Performance:** For the nine months, revenue grew 6% YoY to ₹223 Cr, and profit after tax (PAT) increased 12.5% YoY to ₹35.9 Cr. Quarterly revenue was ₹72.9 Cr (-1% YoY), with PAT...
Jagsonpal Pharma posted strong H1FY26 results: revenue jumped 10.2% YoY to ₹150.1 Cr, and profit (PAT) surged 39.2% to ₹23.4 Cr. Q2FY26 revenue was steady at ₹74.5 Cr, with PAT up 9.7% to ₹12.6 Cr, despite a temporary slowdown from GST 2.0 transition. The company follows an asset-light model, focusing...
**1. Financial Highlights:** Jagsonpal Pharma reported strong Q1FY26: Revenue soared 23.1% YoY to ₹75.6 Cr. Operating EBITDA jumped 24.1% to ₹15.7 Cr (20.8% margin). PAT more than doubled to ₹10.8 Cr (14.3% margin). Gross margins reached 64.4%. Cash balance is robust at ₹160.9 Cr. **2. Strategic Initiatives & Growth Drivers:**...